Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
11.07
-0.09 (-0.81%)
At close: Dec 5, 2025, 4:00 PM EST
11.00
-0.07 (-0.63%)
After-hours: Dec 5, 2025, 6:34 PM EST
Prothena Corporation Revenue
Prothena Corporation had revenue of $2.42M in the quarter ending September 30, 2025, with 148.97% growth. This brings the company's revenue in the last twelve months to $11.79M, down -91.16% year-over-year. In the year 2024, Prothena Corporation had annual revenue of $135.16M with 47.92% growth.
Revenue (ttm)
$11.79M
Revenue Growth
-91.16%
P/S Ratio
50.56
Revenue / Employee
$72,307
Employees
163
Market Cap
595.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
| Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
| Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
| Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
| Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PRTA News
- 16 days ago - Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - Business Wire
- 25 days ago - Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA - Business Wire
- 4 weeks ago - Prothena Reports Third Quarter 2025 Financial Results and Business Highlights - Business Wire
- 5 weeks ago - Prothena to Report Third Quarter 2025 Financial Results on November 6 - Business Wire
- 2 months ago - Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease - Business Wire
- 3 months ago - Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire
- 3 months ago - Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program - Business Wire
- 4 months ago - Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - Business Wire